NCT04482686

Trial of Combination Therapy to Treat COVID-19 Infection

A Phase I Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infection

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: ProgenaBiome · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.

Detailed description

Patients in this trial will undergo treatment for 10 days with either a combination of therapies or placebo. They will then be followed for an additional 20 days.

Conditions

• COVID
• Covid-19
• Corona Virus Infection
• Coronavirus Infection
• Coronavirus-19
• SARS-CoV2
• SARS-CoV Infection

Interventions

Type	Name	Description
DRUG	Ivermectin	Treatment days 1, 4, and 8
DRUG	Doxycycline Hcl	10 day treatment
DIETARY_SUPPLEMENT	Zinc	10 Day treatment
DIETARY_SUPPLEMENT	Vitamin D3	10 day treatment
DIETARY_SUPPLEMENT	Vitamin C	10 day treatment

Timeline

• Start date: 2020-12-09
• Primary completion: 2022-05-15
• Completion: 2022-07-15
• First posted: 2020-07-22
• Last updated: 2024-09-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study